Evidence map›Paper›PMID 32292693›Full record

ArticleJournal of bone oncology2020

Adapting palliative radiation therapy for bone metastases during the Covid-19 pandemic: GEMO position paper.

Sébastien Thureau, Jean Christophe Faivre, Richard Assaker, Emmanuel Biver, Cyrille B Confavreux, Françoise Debiais, Martine Duterque-Coquillaud, Francesco Giammarile, Dominique Heymann, Frédéric E Lecouvet and 4 more

Open access · goldAbstract read
In one paragraph

Article in Journal of bone oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed, 1 pooled it
4.5field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 1 synthesis or guideline pooled it, 24 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Review
  4. Prospective monitoring of patients undergoing radiotherapy during COVID-19.Revista da Associacao Medica Brasileira (1992) · 2024
    Article
  5. Nursing Care for Metastatic Bone Cancer: Trends for the Future.International journal of environmental research and public health · 2023
    Article
  6. Article
  7. Article
  8. Review
  9. Radiotherapy during the COVID-19: a review about management and treatment strategies.Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology · 2022
    Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Review
  15. Radiotherapy imaging: An unexpected ally in fighting COVID 19 pandemic.Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology · 2020
    Article
  16. Response to: Low dose radiation therapy for COVID-19 pneumonia a double-edged sword.Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology · 2020
    Article
  17. Article
  18. Review
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 13 institutions in 3 countries.

Sébastien ThureauRadiation department, Center Henri Becquerel, Quantif-Litis EA 4108, University of Rouen, Rouen, France.
Jean Christophe FaivreRadiation department, Institut de Cancérologie de Lorraine - Alexis-Vautrin, Vandœuvre-lès-Nancy, France.
Richard AssakerUniversity Department of neurosurgery, Lille University Hospital, Lille, France.
Emmanuel BiverDivision of Bone Diseases, Geneva University Hospitals and Faculty of Medicine, University of Geneva, Geneva, Switzerland.
Cyrille B ConfavreuxINSERM UMR 1033 - University of Lyon, Bone Metastasis Expert Center (CEMOS) Cancer Institute of Hospices Civils de Lyon, Rheumatology Department, Centre Hospitalier Lyon Sud, Pierre Bénite, F- 69310 France.
Françoise DebiaisRheumatology department, CHU Poitiers, Poitiers, France.
Martine Duterque-CoquillaudCNRS UMR9020, INSERM UMR1277, University of Lille, Institut Pasteur de Lille, CHU Lille, France.
Francesco GiammarileNuclear Medecine LUMEN, Centre Leon Berard, Lyon, France.
Dominique HeymannInstitut de Cancérologie de l'Ouest, University of Nantes, Inserm, CRCINA, Saint-Herblain, France.
Frédéric E LecouvetInstitut du Cancer Roi Albert 2, Cliniques Universitaires Saint-Luc, Service de Radiologie et d'Imagerie Médicale, Institut de Recherche Expérimentale et Clinique (IREC), Université Catholique de Louvain (UCLouvain), Brussels, Belgium.
Laetitia MorardetOncology Department, Pitié Salpêtrière Hospital, Paris, France.
Frederic PaychaNuclear Medicine Department, Lariboisière University Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France.
Jean-Jacques BodyDepartment of Medicine, CHU Brugmann, Université Libre de Bruxelles (ULB), Brussels, Belgium.
Marie-Hélène VieillardUniversity department of Rheumatology, Lille University hospital; Oscar Lambret Center; CNRS UMR9020, INSERM UMR1277, University of Lille, Institut Pasteur, Lille.
Université de Lille · FRCentre Hospitalier Universitaire de Poitiers · FRCentre Léon Bérard · FRCentre National de la Recherche Scientifique · FRCliniques Universitaires Saint-Luc · BEHôpital Lariboisière · FRInserm · FRInstitut de Cancérologie de Lorraine · FRLaboratoire National Henri Becquerel · FRSorbonne Université · FRUniversité Claude Bernard Lyon 1 · FRUniversité Libre de Bruxelles · BEUniversity of Geneva · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The current health crisis caused by COVID-19 is a challenge for oncology treatment, especially when it comes to radiotherapy. Cancer patients are already known to be very fragile and COVID-19 brings about the risk of severe respiratory complications. In order to treat patients safely while protecting medical teams, the entire health care system must optimize the way it approaches prevention and treatment at a time when social distancing is key to stemming this pandemic. All indications and treatment modalities must be re-discussed. This is particularly the case for radiotherapy of bone metastases for which it is possible to reduce the number of sessions, the frequency of transport and the complexity of treatments. These changes will have to be discussed according to the organization of each radiotherapy department and the health situation, while medical teams must remain vigilant about the risks of complications of bone metastases, particularly spinal metastases. In this short piece, the members of the GEMO (the European Study Group of Bone Metastases) offer a number of recommendations to achieve the above objectives, both in general and in relation to five of the most common situations on radiation therapy for bone metastases.

Identifiers

PMID32292693
PMCPMC7152868
OpenAlexW3015302196

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.